Can you give us patient-specific examples that demonstrate the potential clinical benefits -- improvements in PFS, OS and other metrics -- of whole exome, hybrid capture-based NGS?

Can you give us patient-specific examples that demonstrate the potential clinical benefits -- improvements in PFS, OS and other metrics -- of whole exome, hybrid capture-based NGS?

Can you give us patient-specific examples that demonstrate the potential clinical benefits — improvements in PFS, OS and other metrics — of whole exome, hybrid capture-based NGS?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lia Tsimberidou, MD, PhD

Lia Tsimberidou, MD, PhD

Tenured Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX